COVID-19

Despite the surge in late 2020, a study by Stanford researchers shows just a 10% drop in procedures from 2019 levels.

Screening dipped sharply in 2020 because of the pandemic. The rebound this year is uneven and there is still hesitancy.

COVID-19's latest variant, omicron, could increase the chance that folks will need a fourth vaccine dose earlier than expected, according to executives at Pfizer.

Now in winter, another variant and infections again on the rise, evidence abounds that COVID-19 isn’t finished plaguing, and normalcy’s still a long way off.

The pandemic has been associated with an increase in public health spending, rising mental health issues and a record number of overdose deaths, according to a report from the philanthropic arm of UnitedHealth Group.

A roundup of the latest news about the omicron coronavirus.

A round-up of news about the new variant of the coronavirus.

New research confirms that regardless of age or severity of COVID-19 infection, prolonged effects on cognitive function are possible.

People from racial and ethnic minority groups had higher risks of COVID-19 infections, but outcomes varied based on access to primary care physicians and insurance.

"Given the supply chain constraints that companies are struggling with, the ability to better manage forecasting, demand, and create a redundancy network by allowing for increased visibility into inventory is essential,” recalls Naama Stauber Breckler, CEO of Better Health.

Results of study published in JAMA Oncology suggest that it is the period after chemotherapy when cancer patients are most vulnerable to experiencing a serious case of COVID-19.

The FDA released information on booster shots for the Moderna and Johnson & Johnson COVID-19 vaccines before their public meeting that begins Thursday.

Before the pandemic, rural areas were ahead in telehealth adoption. That has changed during the pandemic, most obviously because many rural residents don’t have access to broadband.

Health officials should consider advise that people spend more time outdoors as. way to cope with this and future pandemics, the researchers suggest.

OSHA issued new "emergency temporary standards" for healthcare employers that create new rules for personal protective equipment (PPE), isolation in case of contact and other measures designed to protect workers and patients from COVID-19.

The next step is for the CDC's Advisory Committee on Immunization Practices to make a decision on whether to add a COVID-19 booster to its recommendations

A recent study reveals longstanding innovation operation issues create a deep-seated risk to corporate growth performance.

Committee's two votes are only recommendations but a narrower booster emergency use authorization now seems likely.

Approvals for a twice-yearly schizophrenia therapy and a seizure drug for infants, a full approval for Keytruda, and a revised EUA for a COVID-19 therapy round out the week.

Almost 95% of U.S. employers surveyed expect to see increased demand for medical services due to employees deferring care because of the pandemic. More than 90% are concerned about their employees’ long-term mental health because of COVID-19, according to a survey of 136 large employers by the Business Group on Health.

Congress wants to cut $1.5 trillion from innovative companies and threaten the loss of one million jobs in order to fund a multi-trillion-dollar spending bill, according to Pharmaceutical Research and Manufacturers of America President and CEO Stephen J. Ubl. This approach would undermine the ability to develop new treatments and jeopardize patient access to life-saving medicines.

With confirmed cases of COVID-19 on the rise in the United States, Cigna has established new requirements to help protect its workforce. Employees who work remotely must be fully vaccinated before entering any U.S. worksite, beginning September 7.

Many people ignored heart disease signs and symptoms during the COVID-19 pandemic — sometimes with grave consequences.

AstraZeneca gets FDA nod for Saphnelo, BMS pulls indication for Istodax, Merck to seek another use for Keytruda, Tecentriq is granted priority review for NSCLC and COVID-19 cocktail gets expanded EUA.

Governments are the only buyers so far, and the amounts they are paying varies.

The pandemic has had dramatically different consequences for the finances of payers and providers.